News & Updates

Use of an ARPI in combination with ADT in a patient with mHSPC

19 Dec 2024 by

A 74-year-old male presented with back pain, right hip pain, and right lower limb weakness in December 2023. He was a chronic smoker and had impaired fasting glucose that was controlled with diet. Work-up in mainland China with CT scan revealed multiple osteolytic lesions in the pelvis and bony spine. Blood test showed elevated serum prostate-specific antigen (PSA) level >300 ng/mL. He was on etoricoxib and acetaminophen for analgesia.

Use of an ARPI in combination with ADT in a patient with mHSPC

19 Dec 2024

CROWN study at 5 years: Sustained benefits with lorlatinib in advanced ALK-positive NSCLC

13 Dec 2024 by

The phase III CROWN trial previously showed that first-line treatment with lorlatinib, a third-generation ALK tyrosine kinase inhibitor (TKI), provided significant survival benefits vs crizotinib in patients with treatment-naïve, advanced, ALK-positive non-small-cell lung cancer (NSCLC). At the 2024 World Conference on Lung Cancer, CROWN investigators discussed the patterns of progression and management of adverse events (AEs) associated with lorlatinib after 5 years of follow-up.

CROWN study at 5 years: Sustained benefits with lorlatinib in advanced ALK-positive NSCLC

13 Dec 2024

[Infographics] Apalutamide in mHSPC: Deep and rapid PSA response correlates with longer rPFS, OS and time to CRPC

04 Dec 2024

Landmark analysis of the phase III TITAN study shows that apalutamide plus ADT has resulted in UL PSA in a larger proportion of mHSPC patients than treatment with ADT alone. Furthermore, deeper and earlier UL PSA decline was associated with improved outcomes, including rPFS and OS.

[Infographics] Apalutamide in mHSPC: Deep and rapid PSA response correlates with longer rPFS, OS and time to CRPC

04 Dec 2024

Ropeginterferon alfa-2b supports a shift in polycythaemia vera treatment

29 Nov 2024

Professor Jean-Jacques Kiladjian, Professor of Clinical Pharmacology, Consultant Haematologist, and head of the Clinical Investigation Centre of Hôpital Saint-Louis & Université Paris Cité in Paris, France, discusses the drawbacks of conventional therapy for PV, and how ropeginterferon alfa-2b may support a shift in treatment.

Ropeginterferon alfa-2b supports a shift in polycythaemia vera treatment

29 Nov 2024

The role of ropeginterferon alfa-2b in the management of polycythaemia vera in SG

29 Nov 2024

MIMS Oncology explores the current landscape of polycythaemia vera management in Singapore and the role of the newly launched ropeginterferon alfa-2b in improving patient outcomes. During an interview, Dr Dawn Mya, a leading haematologist practicing at Parkway Cancer Centre, Singapore, provides expert insights into the therapeutic potential of this novel treatment.

The role of ropeginterferon alfa-2b in the management of polycythaemia vera in SG

29 Nov 2024

Encorafenib plus cetuximab for treatment of BRAFV600E-mutant metastatic colorectal cancer: A case study

28 Nov 2024

Dr Ka On Lam, a specialist in Clinical Oncology in Hong Kong, discusses the current treatment landscape of BRAFV600E-mutant metastatic colorectal cancer (mCRC) and addresses the management challenges associated with patients treated with encorafenib plus cetuximab.

Encorafenib plus cetuximab for treatment of BRAFV600E-mutant metastatic colorectal cancer: A case study

28 Nov 2024

3L EGFR-MET bispecific antibody in a patient with EGFR ex20ins–positive NSCLC after haemorrhagic stroke

19 Nov 2024 by

This was a 60-year-old woman with a history of diabetes and end-stage kidney disease (ESKD) requiring haemodialysis three times a week. She was admitted to the hospital in June 2022 due to shortness of breath and chest tightness lasting for 1 month. Her Eastern Cooperative Oncology Group performance status (ECOG PS) was 2.

3L EGFR-MET bispecific antibody in a patient with EGFR ex20ins–positive NSCLC after haemorrhagic stroke

19 Nov 2024

Two patients with advanced endometrial cancer treated with chemo-IO

05 Nov 2024 by

A 59-year-old female was referred for management of suspected primary carcinoma of the peritoneum in August 2023. She complained of right flank pain and abdominal distention during the previous month. An abdominopelvic (AP) CT scan showed right hydronephrosis and hydroureter along with multiple peritoneal and omental (largest 4.3 x 12.1 x 4.5 cm) masses, as well as a pancreatic tail lesion. There were no enlarged lymph nodes (LNs). Gross ascites and moderate left pleural effusion were present without a pleural mass. Her Eastern Cooperative Oncology Group performance status (ECOG PS) was 1.

Two patients with advanced endometrial cancer treated with chemo-IO

05 Nov 2024

EHA 2024: Elranatamab shows mPFS of nearly 1.5 years in heavily pretreated R/R MM

31 Oct 2024

Elranatamab monotherapy demonstrated a median progression-free survival (mPFS) of 17.2 months and median overall survival (mOS) of >2 years in heavily pretreated patients with relapsed or refractory multiple myeloma (R/R MM) who had received a median of five prior lines of therapy, with no new safety signals, according to long-term follow-up data from the MagnetisMM-3 trial presented at the 29^th Congress of the European Hematology Association (EHA 2024).

EHA 2024: Elranatamab shows mPFS of nearly 1.5 years in heavily pretreated R/R MM

31 Oct 2024

Gilteritinib improves survival in R/R FLT3-mutated AML

15 Oct 2024 by

Patients with relapsed/refractory (R/R) acute myeloid leukaemia (AML) often have poor prognosis and limited succeeding treatment options. In particular, the presence of FMS-like tyrosine kinase 3 (FLT3) gene mutation adversely affects survival outcomes. At an industry-sponsored symposium, Professor Mark Levis from the Johns Hopkins University in Baltimore, US, discussed the role of the oral selective FLT3 inhibitor, gilteritinib, in patients with R/R FLT3-mutated AML, and shared case studies to demonstrate its applicability in select patients in his clinical practice.

Gilteritinib improves survival in R/R FLT3-mutated AML

15 Oct 2024

News & Updates

Filter by Specialty:

Specialty:

Use of an ARPI in combination with ADT in a patient with mHSPC

Use of an ARPI in combination with ADT in a patient with mHSPC

CROWN study at 5 years: Sustained benefits with lorlatinib in advanced ALK-positive NSCLC

CROWN study at 5 years: Sustained benefits with lorlatinib in advanced ALK-positive NSCLC

[Infographics] Apalutamide in mHSPC: Deep and rapid PSA response correlates with longer rPFS, OS and time to CRPC

[Infographics] Apalutamide in mHSPC: Deep and rapid PSA response correlates with longer rPFS, OS and time to CRPC

Ropeginterferon alfa-2b supports a shift in polycythaemia vera treatment

Ropeginterferon alfa-2b supports a shift in polycythaemia vera treatment

The role of ropeginterferon alfa-2b in the management of polycythaemia vera in SG

The role of ropeginterferon alfa-2b in the management of polycythaemia vera in SG

Encorafenib plus cetuximab for treatment of BRAFV600E-mutant metastatic colorectal cancer: A case study

Encorafenib plus cetuximab for treatment of BRAFV600E-mutant metastatic colorectal cancer: A case study

3L EGFR-MET bispecific antibody in a patient with EGFR ex20ins–positive NSCLC after haemorrhagic stroke

3L EGFR-MET bispecific antibody in a patient with EGFR ex20ins–positive NSCLC after haemorrhagic stroke

Two patients with advanced endometrial cancer treated with chemo-IO

Two patients with advanced endometrial cancer treated with chemo-IO

EHA 2024: Elranatamab shows mPFS of nearly 1.5 years in heavily pretreated R/R MM

EHA 2024: Elranatamab shows mPFS of nearly 1.5 years in heavily pretreated R/R MM

Gilteritinib improves survival in R/R FLT3-mutated AML

Gilteritinib improves survival in R/R FLT3-mutated AML